Lv01
0 积分 2024-03-27 加入
Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial
9小时前
待确认
Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
9小时前
已完结
Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)
9小时前
已完结
Global, regional, and national burdens of atopic dermatitis from 1990 to 2021: A trend analysis from the Global Burden of Disease Study 2021
4天前
已完结
Focused update: Guidelines of care for the management of atopic dermatitis in adults
6天前
已完结
Guidelines of care for the management of atopic dermatitis in adults with topical therapies
6天前
已完结
Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies
6天前
已完结
Dupilumab for atopic dermatitis
6天前
已完结
MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic Dermatitis
7天前
已完结
In-vitro activities of essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: A multi-centre study in China, 2021
21天前
已完结
皖公网安备34019202002308
